Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its blockbuster obesity drug, Wegovy (injectable semaglutide). The FDA filing seeks ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...

Manchester City paid the price for making wholesale changes as they slumped to a surprise 2-0 home loss to Bayer Leverkusen in the Champions League. Pep Guardiola's decision to bench a host of big ...

A preliminary study found that adults with type 2 diabetes and a moderate or high risk of cardiovascular disease were less likely to experience a serious cardiovascular event when taking low-dose ...

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals, a development that also helped a rival creating a competing drug. Bayer didn’t ...

FRANKFURT, Nov 24 (Reuters) - Shares in Bayer (BAYGn.DE), opens new tab jumped more than 8% on Monday after initial clinical trial results turned around the fortunes of a key cardiovascular drug that ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

BERLIN, Nov 23 (Reuters) - German pharma company Bayer (BAYGn.DE), opens new tab reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the ...

UMBRELLA IN MY FULL FORECAST. THANK YOU MARY ELLEN. TODAY, HUNDREDS OF NONPROFITS AND ORGANIZATIONS THAT SERVE THE SUSQUEHANNA VALLEY ARE ASKING FOR YOUR DONATIONS AS PART OF THE LARGEST SINGLE DAY ...

A Bayer drug designed to target tumors driven by a rare genetic mutation now has accelerated FDA approval, providing another treatment option for certain patients with advanced cases of lung cancer.